Navigation Links
Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
Date:1/19/2010

uivalence studies.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP).  Its products include LIDODERM®, a topical patch to relieve the pain of postherpetic neuralgia; Percocet® and Percodan® tablets for the relief of moderate-to-moderately severe pain; FROVA® tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA® tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA® ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren® Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; VANTAS® for the palliative treatment of advanced prostate cancer; SUPPRELIN® LA for the treatment of early onset puberty in children; and VALSTAR™ for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable medical risks.  The company markets its branded pharmaceutical products to physicians in pain management, urology, endocrinology, oncology, neurology, surgery and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 The Physician-Patient Alliance ... on July 28, 2015, "Surviving Your Hospital Stay: ... for Patient Safety." A sentence was ... read: "PPAHS is a member of ... Opioids. For more information on the National Coalition to ...
(Date:7/31/2015)...  Xcelience, a contract development and manufacturing organization ... structured cash investment in Powdersize, a ... and powder size classification within the pharmaceutical industry.  ... simultaneously adding a complete set of particle size ... "As we continue to build our ...
(Date:7/31/2015)... PORTLAND, Ore., July 31, 2015  Semler Scientific, Inc. ... and testing services to healthcare insurers and physician groups, ... June 30, 2015. "In the second ... over year revenue growth of 54%, quarter over quarter ... of the installed base of FloChec® units of 18%," ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... SAN DIEGO, Jan. 19, 2012 Sequenom, Inc. (NASDAQ: SQNM ... to market and other conditions, shares of its common stock in ... whether or when the offering may be completed, or as to ... & Company, Inc. is acting as sole book-running manager for the ...
... 19, 2012 Medicare officials should swiftly authorize a Special ... Medicare Part D prescription drug plan if the patient believes ... "preferred network" plan with inadequate pharmacy access, the National ... the start of the 2012 plan year on January 1, ...
Cached Medicine Technology:Sequenom Announces Proposed Public Offering of Common Stock 2Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 2Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 3
(Date:8/1/2015)... In (PRWEB) , ... August 02, 2015 , ... ... month which will help the continuity of care for patients at this natural health ... of the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our ...
(Date:8/1/2015)... ... 01, 2015 , ... Have you ever wondered what “Karma” really means? Does it even exist? ... , Vedic tradition, which gave birth to Hinduism, is one of the most ancient ... of this tradition. According to the wisdom of this heritage, Karma is a very real ...
(Date:8/1/2015)... ME (PRWEB) , ... August 01, 2015 , ... Tina ... Retail Champions.” , Wilcoxson was given that honor by the National Retail Federation, the ... retail industry. Wilcoxson was one of three Maine business owners to be named as ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, Symantec released a security ... have been behind the attack on Anthem Inc. which resulted in one of the ... hole attacks and spear phishing campaigns. , For Joe Caruso, founder and ...
(Date:8/1/2015)... ... , ... “ reTXT ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... and delete any message including ones already sent. , While text messaging has more ...
Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Local Retail Advocate Wins National Recognition 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2
... 24 The Baylor Charles A. Sammons Cancer Center has ... clinical trials cooperative groups in the United States. Funded by ... conducts clinical trials to prevent and treat cancer in adults, ... , "Joining this prestigious group will allow us to offer ...
... , Easter Seals New York and the New York State ... to local families in Port Jervis, New York , PORT ... Seals New York, in partnership with the New York State ... Easter Seals New York,s Child Development Center, Project Discovery in ...
... HARRISBURG, Pa., Nov. 24 Governor Edward G. Rendell ... flu were vaccinated during the weekend at public health ... health departments. , "With the federal government unable ... of H1N1 vaccine, distribution has been challenging," said Governor ...
... Ill., Nov. 24 Dr. Nelson Escobar, a physician with ... the James Brady Award. The award was presented to ... their annual conference on October 30, 2009. , According ... award in recognition of his expertise in addressing the complex ...
... may help ward off peripheral artery disease, researchers ... people aged 75 and older, the herbal supplement Ginkgo ... a new study finds. , There is some evidence ... leg-circulation problem known as peripheral artery disease, however. , ...
... PHILADELPHIA Researchers have found that hormones produced during ... of breast cancer. This protein, alpha-fetoprotein (AFP), may serve ... prevention of breast cancer, according to findings published in ... American Association for Cancer Research. "Hormones in ...
Cached Medicine News:Health News:Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups 2Health News:Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups 3Health News:Fraternal Order of Police Provides Food and Hope for Families in Port Jervis this Thanksgiving 2Health News:Governor Rendell Announces 100,000 At-Risk Pennsylvanians Vaccinated at H1N1 Public Health Clinics; Addresses Future Vaccine Distribution Plans 2Health News:Marianjoy Medical Group Physician Receives James Brady Award 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 3Health News:Protein from pregnancy hormone may prevent breast cancer 2